Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

60.01 +0.98 (+1.65%)
Streaming Delayed Price Updated: 11:23 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
What's Next: Rhythm Pharmaceuticals's Earnings Preview
Via Benzinga
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals
Via Benzinga
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
Via Benzinga
The 3 Best Nasdaq Stocks to Buy in May 2024
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May. 
Via InvestorPlace
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest. 
Via Benzinga
The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts
Via Benzinga
Analyst Expectations for Rhythm Pharmaceuticals's Future
Via Benzinga
Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial
During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and... 
Via Benzinga
Rhythm Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
A Preview Of Rhythm Pharmaceuticals's Earnings
Via Benzinga
Expert Ratings for Rhythm Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Preview: Rhythm Pharmaceuticals's Earnings
Via Benzinga
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Morgan Stanley Maintains Equal-Weight Rating for Rhythm Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC)... 
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
3 Breakout Growth Stocks to Buy for the Long Haul
These three have had big-time share gains backed up by breakthrough science. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.